Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     
Research

Genetic silencing treatment effective against dry eye

04/06/2018
Pharmaceutical company Sylentis has said research into its tivanisiran treatment for dry eye disease (DED) showed it improved ocular inflammatory parameters and tear quality, while also resulting in a reduction in ocular pain.

The company said the findings, presented at the Association for Research in Vision and Ophthalmology (ARVO), had enabled it to begin a Phase III “Helix” clinical trial.

Tivanisiran’s mechanism for treating DED is based on genetic silencing through RNA interference (RNAi), which is targeted at the treatment of the signs and symptoms of this pathology.

“We trust in our technology, innovative in this field, and we hope that tivanisiran will soon become a real alternative for the treatment of millions of people that suffer dry eye disease around the world,” director of R&D at Sylentis Ms Ana Isabel Jiménez said.

"Tivanisiran’s mechanism for treating DED is based on genetic silencing through RNA interference (RNAi)"

“This is a significant step forward in the development of innovative drugs in different therapeutic areas through a novel technology of genetic silencing based on the RNA.”

Administered as preservative-free eye drops, tivanisiran selectively inhibits production of the transient receptor potential cation channel (TRPV1), which mediates the transmission of ocular pain.

Acording to Sylentis, non-clinical studies already conducted have demonstrated tivanisiran has the ability to inhibit this specific target and block the perception of ocular pain in animals.

Sylentis says it is one of the few RNAi research companies in Europe that applies this technology to the field of ophthalmology, which extends to research on new therapies for ophthalmological and inflammatory illnesses.

The “Helix” study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy. It has recruited 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.

largeleaderboard_0817
advertisement


standardlarge_0218
advertisement
Editor's Suggestion
Hot Stories

AND/OR
 

Subscribe for Insight in your Inbox

Get Insight with the latest in industry news, trends, new products, services and equipment!